Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jan 13;10(1):10.
doi: 10.3390/pharmaceutics10010010.

Ophthalmic Drug Delivery Systems for Antibiotherapy-A Review

Marion Dubald  1   2 , Sandrine Bourgeois  3   4 , Véronique Andrieu  5 , Hatem Fessi  6   7
Affiliations
Review

Ophthalmic Drug Delivery Systems for Antibiotherapy-A Review

Marion Dubald et al. Pharmaceutics. .

Abstract

The last fifty years, ophthalmic drug delivery research has made much progress, challenging scientists about the advantages and limitations of this drug delivery approach. Topical eye drops are the most commonly used formulation in ocular drug delivery. Despite the good tolerance for patients, this topical administration is only focus on the anterior ocular diseases and had a high precorneal loss of drugs due to the tears production and ocular barriers. Antibiotics are popularly used in solution or in ointment for the ophthalmic route. However, their local bioavailability needs to be improved in order to decrease the frequency of administrations and the side effects and to increase their therapeutic efficiency. For this purpose, sustained release forms for ophthalmic delivery of antibiotics were developed. This review briefly describes the ocular administration with the ocular barriers and the currently topical forms. It focuses on experimental results to bypass the limitations of ocular antibiotic delivery with new ocular technology as colloidal and in situ gelling systems or with the improvement of existing forms as implants and contact lenses. Nanotechnology is presently a promising drug delivery way to provide protection of antibiotics and improve pathway through ocular barriers and deliver drugs to specific target sites.

Keywords: antibiotics; drug delivery; nanoparticles; ocular drug administration.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Schematic illustration of ocular structures and barriers.
Figure 2
Figure 2
Routes of ocular administration.
Figure 3
Figure 3
Schema of micro- and nanostructure intended for ocular drug delivery.
See this image and copyright information in PMC

References

    1. Gan L., Wang J., Jiang M., Bartlett H., Ouyang D., Eperjesi F., Liu J., Gan Y. Recent advances in topical ophthalmic drug delivery with lipid-based nanocarriers. Drug Discov. Today. 2013;18:290–297. doi: 10.1016/j.drudis.2012.10.005. - DOI - PubMed
    1. Le Bourlais C., Acar L., Zia H., Sado P.A., Needham T., Leverge R. Ophthalmic drug delivery systems—Recent advances. Prog. Retin. Eye Res. 1998;17:33–58. doi: 10.1016/S1350-9462(97)00002-5. - DOI - PubMed
    1. Achouri D., Alhanout K., Piccerelle P., Andrieu V. Recent advances in ocular drug delivery. Drug Dev. Ind. Pharm. 2013;39:1599–1617. doi: 10.3109/03639045.2012.736515. - DOI - PubMed
    1. Yellepeddi V.K., Palakurthi S. Recent advances in topical ocular drug delivery. J. Ocul. Pharmacol. Ther. Off. J. Assoc. Ocul. Pharmacol. Ther. 2016;32:67–82. doi: 10.1089/jop.2015.0047. - DOI - PubMed
    1. Kalhapure R.S., Suleman N., Mocktar C., Seedat N., Govender T. Nanoengineered drug delivery systems for enhancing antibiotic therapy. J. Pharm. Sci. 2015;104:872–905. doi: 10.1002/jps.24298. - DOI - PubMed